Triple Negative Breast Cancer Update: Immunotherapy in stage 2-3 TNBC (KEYNOTE 522 Update)

[@dataprogramming-j3q]

informative thanks eleoora

[@Salriaraj20]

Nice talk,
1. What was the denominator for trial.
2. What age group involved
3. How many people have not responded to immunotherapy
4. How many have serious side effects in 3 to 5 year after initial treatment.
If you may, please share the results it would be appreciated. Thank you
Raj Salaria